Dehaier profits are 70 percent higher | Earnings roundup

March 9, 2011 By MassDevice staff

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

Here’s a quick rundown of a few releases over the past couple days:

Dehaier profits are 70 percent higher
Dehaier Medical Systems Ltd. (NSDQ:DHRM) reported profits of $1.5 million or 32 cents per diluted share, on sales of $6.7 million during the three months ended Dec. 31. That compares with profits of $621,641, or 20 cents per diluted share, on sales of $2.9 million during the same period last year.

Full-year profits were $4.6 million, or $1.09 per diluted share, on sales of $19.6 million. That compares with profits of $2.7 million, or 89 cents per diluted share, on sales of $12.4 million in 2009.
Read more

Neoprobe 2010 losses widen more than 25 percent, but sales get 13 percent bump
Neoprobe Corp. (NYSE Amex:NEOP) reported losses of $2.1 million, or 3 cents per diluted share, on sales of $3.2 million during the three months ended Dec. 31. That compares with a losses of $293,638, or less than 1 cents per diluted share, on sales of $2.4 million during the same period in 2009.

Full-year losses were $50.0 million, or 72 cents per diluted share, on sales of $10.7 million. That compares with losses of $39.8 million, or 54 cents per diluted share, on sales of $9.5 million in 2009.
Read more

Elekta on the rise
Elekta AB (STO:EKTA-B) reported net income of $30.1 million on sales of $280.8 million during the three months ended Jan. 31, 2011. That compares with net income of $22.7 million on sales of $262.3 million during the same period in 2009.
Read more

RBC sales, profits see increases
RBC Life Sciences Inc. (OTC:RBCL) reported profits of $558,000, or 2 cents per diluted share, on sales of $28.2 million in the year ended Dec. 31, 2010. That compares with a loss of $335,000, or 2 cents per diluted share, on sales of $24.9 million for 2009.
Read more

Cerus cuts losses after increased sales
Cerus Corp. (NSDQ:CERS) reported losses of $2.6 million or 6 cents per diluted share, on sales of $6.0 million during the three months ended Dec. 31. That compares with losses of $4.9 million, or 13 cents per diluted share, on sales of $5.2 million during the same period last year.

Full-year losses were $16.9 million, or 42 cents per diluted share, on sales of $21.7 million. That compares with losses of $24.1 million, or 69 cents per diluted share, on sales of $16.8 million in 2009.
Read more

DexCom sales more than double, but losses worsen
DexCom Inc. (NSDQ:DXCM) reported losses of $9.8 million, or 16 cents per diluted share, on sales of $13.6 million during the three months ended Dec. 31. That compares with losses of $11.5 million, or 25 cents per diluted share, on sales of $6.6 million during the same period last year.

Full-year losses were $55.2 million, or 97 cents per diluted share, on sales of $40.2 million. That compares with losses of $53.5 million, or $1.21 per diluted share, on sales of $18.0 million in 2009.
Read more

American Shared Hospital Services reports stagnant sales
American Shared Hospital Services (NYSE Amex:AMS) reported profits of $40,000, or 1 cent per diluted share, on sales of $4.2 million during the three months ended Dec. 31. That compares with a loss of $137,000 or 3 cents per diluted share, on sales of $4.1 million during the same period last year.

Full-year profits were $57,000, or 1 cent per diluted share, on sales of $16.7 million. That compares with a loss of $188,000, or 4 cents per diluted share, on sales of $16.8 million in 2009.
Read more

GenMark losses ease after sales rocket more than 150 percent
GenMark Diagnostics Inc. (NSDQ:GNMK) reported losses of $3.5 million, or 30 cents per diluted share, on sales of $787,482 during the three months ended Dec. 31, 2010. That compares with losses of $5.6 million, or $1.07 per diluted share, on sales of $302,410 during the same period in 2009.

Full-year losses were $18.4 million, or $1.88 per diluted share, on sales of $2.5 million. That compares with losses of $20.0 million, or $4.41 per diluted share, on sales of $998,416 in 2009.
Read more

IRIDEX profits get 15 percent bump on modest sales increase
IRIDEX Corp. (NSDQ:IRIX) reported profits of $837,000, or 8 cents per diluted share, on sales of $12.2 million during the three months ended Jan. 1, 2011. That compares with profits of $517,000, or 5 cents per diluted share, on sales of $11.6 million during the same period in 2009.

Full-year profits were $3.0 million, or 30 cents per diluted share, on sales of $43.7 million. That compares with profits of $2.6 million, or 26 cents per diluted share, on sales of $43.2 million in 2009.
Read more

Safeguard Scientifics’ Q4 beats year
Safeguard Scientifics Inc. (NYSE:SFE) reported profits of $45.4 million, or $1.84 per diluted share, on revenue of $0 during the three months ended Dec. 31, 2010. That compares with losses of $58.0 million, or $2.85 per diluted share, on revenue of $0 during the same period in 2009.

Full-year profits were $27.1 million, or $1.26 cents per diluted share, on revenue of $0. That compares with profits of $68.8 million, or $3.14 per diluted share, on revenue of $34.8 million in 2009.
Read more

Ga. warehouse workers sue Sterigenics, ConMed over EtO exposure
Fifty-three people who worked in an Atlanta-area warehouse that stored medical devices sterilized by ethylene oxide (EtO) filed suit this week against Sterigenics and its parent company over exposure to the gas. The plaintiffs or their families claim that long-term EtO exposure to the sterilized devices, which they unloaded, handled, warehoused and distributed, caused multiple… […]
FDA eases regs on certain device changes during pandemic
The FDA will allow limited changes to certain devices so medtech companies can address manufacturing and supply chain issues due to COVID-19-related disruptions. In a guidance released yesterday, the agency said it would allow changes to devices approved through its premarket approval (PMA) and humanitarian device exemption (HDE) pathways as long as those changes do… […]
15 heart devices that could boost their manufacturers’ sales
Before the coronavirus pandemic hit, medtech companies large and small were making notable news with a number of innovative heart devices. Some of these same companies took a big hit to their bottom lines when the danger of spreading COVID-19 and using up precious personal protective equipment convinced hospitals to limit non-urgent procedures. Now hospitals… […]
This wearable could help people practice safe distancing amid COVID-19
Imec spinoff Lopos, with the Ghent University (Belgium) announced the Lopos SafeDistance wearable for promoting safety during the COVID-19 pandemic. As businesses attempt to return to in-person activities, the collaboration designed the wearable device to warn employees through an audible or haptic alarm when they are violating social distancing guidelines as they approach each other.… […]
FDA launches COVID-19 research initiative
The FDA has entered an agreement with healthcare analytics company Aetion to research urgent questions about COVID-19. The New York City-based company said the research will support FDA objectives to explore the natural history of the disease, as well as treatment and diagnostic patterns using relevant, novel data sources and analyzing these data according to well-established principles.… […]
Medtronic execs see quick recovery, increased M&A
If Medtronic’s troubling Q4 report offers a snapshot of a company hit hard by COVID-19, the next image in the sequence may show a faster-than-expected recovery and increased merger-and-acquisition of smaller companies. In the quarterly call on Thursday morning, Medtronic CEO Geoff Martha and CFO Karen Parkhill expressed optimism that the company’s businesses already are showing signs… […]
Webinar: How COVID-19 is changing medical device regulation, clinical trials and reimbursement
Tuesday, June 23, 2020 11:30 a.m. eastern time / 8:30 a.m. pacific time As the life sciences industry works to contain the COVID-19 outbreak, it is clear that the dynamics of the medical device and digital health industries are being disrupted. Going virtual is the new normal and executives of medtech and healthtech… […]
IMDRF recommends UL 2900 compliance for medical device cybersecurity
By Stewart Eisenhart, Emergo Group Recent guidance published by the International Medical Devices Regulators Forum (IMDRF) that covers medical device cybersecurity best practices includes recommendations that manufacturers comply with the UL 2900 set of standards for network-connectable devices. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post… […]
Goddard teams with Swab56 on COVID-19 test swabs
Mechanical engineering and industrial design company Goddard announced that it is working with the Swab56 Project to rapidly increase the production of Swab56’s test swabs, which are used in healthcare facilities to test for COVID-19. As news reports have documented, traditional nasopharyngeal swabs are in short supply as healthcare facilities around the world struggle to keep… […]
This patient-mover got an emergency COVID-19 nod from the FDA
AR Tech, a division of A&R Tarpaulins, announced today that the FDA has granted an EUA for its Patient Isolation Transportation Unit (PITU) to help hospitals better manage the COVID-19 pandemic. “PITU is a game-changer in this fight against the pandemic because it is a negative pressure isolation enclosure that makes working with highly contagious diseases… […]
Sommetrics lands ISO 13485 certification
Sleep apnea treatment device startup Sommetrics announced yesterday that its quality management system has been certified to the ISO 13485:2016 standard. During the audit process required for certification, Sommetrics was also evaluated and found to be in compliance with the standards of the Medical Device Single Audit Program (MDSAP) for Canada. “This is an important… […]